Optimal sequencing of the first- and second-line target therapies in metastatic renal cell carcinoma: based on nationally representative data analysis from the Korean National Health Insurance System

The authors intend to compare the effects of each targeted therapy (TT) in the treatment of patients with metastatic renal cell carcinoma (mRCC) using big data based on the Korean National Health Insurance System (NHIS) and determine the optimal treatment sequence. Data on the medical use of patient...

Full description

Saved in:
Bibliographic Details
Published in:BMC cancer 2023-05, Vol.23 (1), p.483-483, Article 483
Main Authors: Kang, Dong Hyuk, Lee, Joo Yong, Lee, Yunhee, Ha, U-Syn
Format: Article
Language:English
Subjects:
Antimitotic agents
Antineoplastic agents
Antineoplastic Agents - therapeutic use
Axitinib
Axitinib - therapeutic use
Cabozantinib
Cancer therapies
Carcinoma, Renal cell
Carcinoma, Renal Cell - drug therapy
Carcinoma, Renal Cell - genetics
Care and treatment
Comorbidity
Complications and side effects
Development and progression
Diagnosis
Dosage and administration
Humans
Internal medicine
Kidney cancer
Kidney Neoplasms - drug therapy
Kidney Neoplasms - genetics
Medical prognosis
Metastases
Metastasis
National health insurance
Nephrectomy
Patients
Pazopanib
Prescription drugs
Renal cell carcinoma
Republic of Korea - epidemiology
Statistical analysis
Sunitinib
Sunitinib - therapeutic use
Survival analysis
Urology
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The authors intend to compare the effects of each targeted therapy (TT) in the treatment of patients with metastatic renal cell carcinoma (mRCC) using big data based on the Korean National Health Insurance System (NHIS) and determine the optimal treatment sequence. Data on the medical use of patients with kidney cancer were obtained from the NHIS database from January 1, 2002, to December 31, 2020. Patient variables included age, sex, income level, place of residence, prescribing department, and duration from diagnosis to the prescription date. The primary outcome was overall survival (OS) for each drug and sequencing. We performed propensity score matching (PSM) according to age, sex, and Charlson Comorbidity Index based on the primary TTs. After 1:1 PSM, the sunitinib (SUN) (n = 1,214) and pazopanib (PAZ) (n = 1,214) groups showed a well-matched distribution across the entire cohort. In the primary treatment group, PAZ had lower OS than SUN (HR, 1.167; p = 0.0015). In the secondary treatment group, axitinib (AXI) had more favorable OS than cabozantinib (CAB) (HR, 0.735; p = 0.0118), and everolimus had more adverse outcomes than CAB (HR, 1.544; p 
ISSN:1471-2407
1471-2407
DOI:10.1186/s12885-023-10991-3